Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems
“Schizophrenia is arguably the worst disease affecting mankind, even AIDS not excepted”. Since this statement in 1988 (Editors, 1988), schizophrenia still remains a major challenge to medicine, with up to 60% of patients not responding adequately to treatment despite the relatively large arsenal of...
| Autores: | , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | Brasil |
| Recursos: | Universidade Federal do Rio Grande do Norte (UFRN) |
| Repositorio: | Repositório Institucional da UFRN |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.ufrn.br:123456789/25459 |
| Acesso em linha: | https://repositorio.ufrn.br/jspui/handle/123456789/25459 https://doi.org/10.1016/j.schres.2014.08.020 |
| Access Level: | acceso abierto |
| Palavra-chave: | Sodium nitroprusside |
| Resumo: | “Schizophrenia is arguably the worst disease affecting mankind, even AIDS not excepted”. Since this statement in 1988 (Editors, 1988), schizophrenia still remains a major challenge to medicine, with up to 60% of patients not responding adequately to treatment despite the relatively large arsenal of antipsychotics currently available. By modulating the nitric oxide (NO) pathway, a new paradigm for schizophrenia treatment apparently involving modulation of nitric oxide (NO) has been proposed (Oliveira et al., 2011). |
|---|